- Price
- $494.63
- Day
- -0.53%
- Mkt Cap
- $21.00B
- 52W Range
- $409.07 – $609.35
- Volume
- 1.47M
- Beta
- 0.56
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Corient Private Wealth LP reduced its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by 35.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,429 shares of the biotechnology company's stock after selling 7,513 shares during the quarter. Corient Private Wealth LP's
Read full article
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Read full article
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $504.12, for a total transaction of $4,789,140.00. Following the completion of the sale, the chief executive officer owned 324,443
Read full article
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $502.35, for a total value of $4,772,325.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in
Read full article
United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Volatility and Risk United Therapeutics has a beta
Read full article
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article
United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase the company's common stock, for approximately $477.6 million. T.
Read full article
Hsbc Holdings PLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,125 shares of the biotechnology company's stock after purchasing an additional 7,890 shares during
Read full article
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Read full article
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
Read full article